Milestone Pharmaceuticals (MIST) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

MIST Milestone Pharmaceuticals

Watchlist

1.850
-0.010-0.54%

Close Nov 21 16:00 ET

1.810
-0.040-2.16%

Post 17:56 ET

98.66MMarket Cap-2312P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook Is Bright
Yahoo FinanceNov 19 09:55 ET
Piper Sandler Maintains Milestone Pharmaceuticals(MIST.US) With Buy Rating, Maintains Target Price $5
Moomoo NewsNov 13 08:36 ET · Ratings
Milestone Pharmaceuticals (MIST) Gets a Buy From Piper Sandler
TipRanksNov 13 08:22 ET · Ratings
Strategic Positioning and Financial Outlook: Ritu Baral's Buy Rating on Milestone Pharmaceuticals Amidst Etripamil's Promising Market Launch
TipRanksNov 13 00:15 ET · Ratings
Express News | Milestone Pharmaceuticals Files for Mixed Shelf Offering of up to $250 Mln - SEC Filing
ReutersNov 12 16:40 ET
Milestone Pharmaceuticals Prepares for CARDAMYST Approval
TipRanksNov 12 11:38 ET

Comments

Clintzilla

Oct 12 14:14

$Milestone Pharmaceuticals (MIST.US)$ no comments since January... means.. they dipped it to steal it and hoard it, accumulate it.. PDUFA next year.. hmm

Jaguar8

Sep 6 06:54

NEWS

$Milestone Pharmaceuticals (MIST.US)$
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced its licensing partner, Ji Xing Pharmaceuticals Ltd, released positive topline re...

Jaguar8

Aug 22 07:05

NEWS

$Milestone Pharmaceuticals (MIST.US)$
Rodman & Renshaw Initiates Coverage On Milestone Pharmaceuticals with Buy Rating, Announces Price Target of $9

Jaguar8

May 29 06:18

NEWS

$Milestone Pharmaceuticals (MIST.US)$
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST™
Milestone Pharmaceuticals announced the FDA's acceptance of its New Drug Application for CARDAMYST, an etripamil nasal spray intended for managing paroxysmal supraventricular tachycardia (PSVT). This milestone occurred on May 26, 2024, with a Prescription Drug User Fee Act (PDUFA) target date set for ten months later. The clinical trial program for CARDAMYST is the l...

Jaguar8

May 2 07:01

$Milestone Pharmaceuticals (MIST.US)$
NEWS
Milestone® Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

MIST Milestone Pharmaceuticals

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target